文献速递细菌感染、耐药与抗菌药物

耐甲氧西林假中间葡萄球菌克隆演变与耐药时空变化

Evolving landscape of methicillin-resistant Staphylococcus pseudintermedius: the emergence of new epidemic waves across Europe, Asia and North America.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

结果显示2013年后MRSP克隆结构发生转变,历史优势谱系(欧洲CC71、北美CC68、亚洲CC45)下降,而CC551全球出现,北美CC556和CC1431、亚洲CC363和CC1631新发。北美非β-内酰胺类耐药上升(氯霉素6%-59%),欧洲除四环素外基本稳定,亚洲下降;CC71耐药率最高且更常来自临床样本。

要点

  • 2013年后MRSP克隆结构转变,CC551全球出现,区域新谱系替代历史优势克隆。
  • 北美氯霉素耐药从6%升至59%,欧洲除四环素外稳定,亚洲耐药下降。
  • CC71耐药率最高且更可能分离自临床样本,提示克隆与耐药及致病性关联。

核心结论

  • MRSP克隆结构在2013年后发生全球性演变,新流行克隆出现并伴随区域特异性耐药变化。
  • 特定CC与耐药模式及样本来源的关联可解释流行病学变化,包括区域抗菌药物使用差异和新兴谱系的适应性优势。

研究设计与样本

  • 采用多项逻辑回归(MLR)和贝叶斯回归模型(BRM)评估CC与样本类型、洲际及时间段的关联,MLR结果输入BRM。

主要发现

  • 2013年后MRSP克隆结构转变:欧洲CC71、北美CC68、亚洲CC45等历史优势谱系下降。
  • 全球出现CC551,北美出现CC556和CC1431,亚洲出现CC363和CC1631。
  • 北美非β-内酰胺类耐药增加,尤其氯霉素从6%升至59%;欧洲除四环素外基本稳定;亚洲耐药下降。
  • CC71耐药率最高,且更可能分离自临床样本。

关键数值与推荐

  • 北美氯霉素耐药率从6%升至59%。
  • CC71在耐药率和临床样本分离可能性上均高于其他CC。

临床怎么用

  • 提示临床应关注MRSP克隆演变和区域耐药差异,尤其北美氯霉素耐药上升。
  • CC71高耐药且多见于临床样本,经验性用药需参考本地耐药监测数据。
  • 强调持续全球监测克隆多样性、抗菌药物使用与耐药趋势的必要性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aims to identify spatiotemporal variations in clonal diversity and antimicrobial resistance of methicillin-resistant Staphylococcus pseudintermedius (MRSP). MATERIALS AND METHODS: A PubMed search (June 2016-December 2023), combined with data from PubMLST and a previous review (September 2007-May 2016), identified 2654 isolates. Multinomial logistic regression (MLR) and Bayesian regression models (BRMs) were used to assess associations between clonal complexes (CCs) and variables (sample type, continent and period), with MLR results feeding into the BRM. RESULTS: A shift in MRSP clonal structure was observed after 2013. A decline in the prevalence of historically dominant lineages, such as CC71 in Europe, CC68 in North America and CC45 in Asia, coincided with the global emergence of CC551, as well as CC556 and CC1431 in North America, and CC363 and CC1631 in Asia. Resistance to non-β-lactams increased in North America, particularly for chloramphenicol (6%-59%), remained largely stable in Europe except for tetracycline, and decreased in Asia. Striking differences among CCs were observed, with CC71 exhibiting the highest resistance rates and a greater likelihood of being isolated from clinical samples. DISCUSSION: The observed associations between specific CCs and resistance patterns provide valuable insights into the factors driving these epidemiological changes, including regional antimicrobial use patterns (e.g. chloramphenicol usage in North America) and potential fitness advantages of emerging lineages. These dynamics parallel those seen in methicillin-resistant Staphylococcus aureus. CONCLUSION: The evolving MRSP landscape highlights the need for sustained global surveillance to monitor clonal diversity, antimicrobial use and resistance trends.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Giarratana LR, Pirolo M, Roch FF, et al. Evolving landscape of methicillin-resistant Staphylococcus pseudintermedius: the emergence of new epidemic waves across Europe, Asia and North America. J Antimicrob Chemother. 2026. PMID: 41013946. doi:10.1093/jac/dkaf340

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。